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by Elsevier B.V. This is an open accesAbstract Objective: Methotrexate (MTX) is a chemotherapeutic agent that functions as a fo-
lic acid antagonist. The frequency of high dose methotrexate (HDMTX)-associated toxicity is
variable. In this study, we investigated the frequency of myelosuppression and hepatotoxicity
7 days after HDMTX infusion.
Methods: This study included children diagnosed with acute lymphoblastic leukemia (ALL) be-
tween January 2010 and April 2015. The patient blood counts and biochemical parameters
measured before and after 7 days of HDMTX infusion were retrospectively recorded. We as-
sessed HDMTX infusions for 48 children. The number of patients and drug doses included the
following: 17 children receiving 1 g/m2 (68 infusions), 14 children receiving 2 g/m2 (56 infu-
sions), and 17 children receiving 5 g/m2 (68 infusions). The classification of toxicity was made
based on the Common Terminology Criteria for Adverse Events (CTCAE) 2010 criteria. Myelo-
suppression was defined as a hemoglobin level <10 g/L and absolute neutrophil count
<1  109/L or platelet count <75  109/L. The presence of transaminase levels 5 times
the upper limit was considered to be hepatotoxicity grade 3. The MTX levels at 42 h in pa-
tients with and without toxicity were compared to evaluate the correlation between MTX
levels, hematologic parameters and transaminase levels.
Results: Myelotoxicity was observed in 35.2%, 37.5%, and 33.8% of the infusions and hepatotox-
icity grade 3 was detected in 13.2%, 12.5% and 11.7% of the infusions in patients receiving 1, 2
and 5 g/m2 HDMTX after 7 days, respectively. There was no statistically significant difference
between MTX levels at 42 h in patients with and without toxicity (P > .05, for all). There was no
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the hematologic toxicity increased after repeated cycles in patients receiving 5 g/m2. Howev-
er, the hepatic toxicity decreased with additional cycles. Our results show the level of MTX at
42 h is not effective to identify toxicity.
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1231. Introduction
Methotrexate inhibits dihydrofolate reductase and was
initially developed as an anti-cancer treatment in the 1940s
[1]. The most commonly described side-effects of high dose
methotrexate (HDMTX) therapy are myelosuppression, oral
mucositis, and acute liver toxicity with transient elevation
of transaminase levels [1]. These adverse effects increase
the risk of infection, which can delay the scheduled ther-
apy. There is a difference between methotrexate (MTX)
associated myelosuppression and toxicity. MTX-associated
toxicity is related to several factors including drug dose,
the duration of administration, patient risk factors, and
genetic factors [2,3]. In addition, the criteria used to assess
toxicity are variable. For example, a study showed the most
common toxicity was hematologic toxicity and 64e87% of
the patients developed grade 3 and higher toxicity [3,4].
The incidence of transient high levels of transaminase was
reported as 64% [5]. There are currently no data regarding
the use of HDMTX pharmacokinetic and toxicity information
to predict hepatic and hematologic toxicity in children with
acute lymphoblastic leukemia. Csordas et al [6] determined
there is no correlation between MTX level and hematologic
toxicity. However, Rask et al [4] reported there is a rela-
tionship between elevated serum MTX levels and hemato-
logic toxicity.
In this study, we aimed to determine the hepatic and
hematologic toxicity frequency and assessed whether there
is a significant relationship between treatment toxicity and
MTX42 levels in children taking different doses of HDMTX.
2. Materials and methods
This study included 48 children diagnosed with ALL at
Eskis‚ehir Osmangazi University Faculty of Medicine, Pedi-
atric Hematology/Oncology Department between January
2010 and April 2015. The age, gender, leukemia immune
phenotype, and the administered HDMTX doses were
retrospectively recorded from the file records. The patient
hemoglobin (Hb), absolute neutrophil count (ANC), platelet
(PLT) count and aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) levels were recorded
before MTX administration and on the 7th day following
drug infusion.
The patients were stratified into three risk groups. The
first risk group was defined using the following criteria: (1)
Standard risk (SR) patients have an initial leukocyte
count < 20  109/L and age 1 year or <6 years and ab-
solute blast count in the peripheral blood on day 8 after 7O¨zdemir ZC, et al., The frequenc
e, International Journal of Pediatdays of prednisolone treatment <1  109/L and M1 (<5%
blasts) or M2 (5% to< 25% blasts) marrow on day 15, and
M1 marrow on day 33 (all criteria must be fulfilled). The
second group (2) was the high risk (HR) group and is defined
as at least one of the following: absolute blast count in the
peripheral blood on day 8 after 7 days of prednisolone
treatment >1  109/L, M3 marrow on day 15, M2 or M3
marrow on day 33, t (9; 22) (BCR-ABL), or t (4; 11) (MLL-
AF4), or hypodiploidy  45. The third group (3) was the
Intermediate risk (IR) grouped and was defined as the pa-
tients who were classified as neither SR nor HR. The HR
patients were not included in the study because their
consolidation treatment is different.
All patients received 4 HDMTX infusions at 2-week in-
tervals on days 8, 22, 36, and 50 of the consolidation phase.
The patients also received oral 6-mercaptopurine (6MP) at
a dose of 25 mg/m2/day continuously during the consoli-
dation phase of chemotherapy in addition to HDMTX. Any
concurrent treatment with trimoxazole was paused in all
patients 2 days before and 3 days after the HDTMX infusion.
We excluded patients whose absolute neutrophil count was
<1  109/L with a platelet count <75  109/L or had liver
function tests above the upper limits before the HDMTX
infusion.
The patients received 3 different doses of HDMTX. The
preB ALL SR patients received 2 g/m2, which is in accor-
dance with the ALL-IC BFM 2009 protocol. The preB ALL IR
and T ALL SR/IR patients received 5 g/m2 of HDTMX. Ac-
cording to BFM TRALL 2000 protocol, preB ALL SR/IR pa-
tients received 1 g/m2 of HDTMX. As per BFM TRALL 2000
protocol the 1 g/m2 was given within 36 h and as per the
ALLIC BFM 2009 protocol the doses of 2 and 5 g/m2 were
administered via 24-h of infusion. Alkalization was used to
maintain the urine pH  7 from 4 h through þ72 h after
the start of the MTX infusion. The urine was tested by
dipstick. Briefly, a bolus infusion of 2 mmol/kg NaHCO3 with
2 ml/kg distilled water was delivered over 1 h. Thereafter,
500 ml 0.45% NaCl/5% dextrose þ40 mmol NaHCO3 þ 10 ml
KCl 7.45% hydration fluid was administered during 4 h. The
HDMTX infusion was started only when a urine pH was
greater than 7. The bolus infusion was repeated if the urine
pH was less than 7. All patients received a loading dose of
methotrexate as 1/10 of the total MTX dose over 30 min.
The remaining 9/10 dose was given over the following 23 h
30 min or 35 h 30 min for children treated with 2 g/m2, 5 g/
m2 and 1 g/m2, respectively. We provided a total 3000 ml/
m2 parallel hydration with 0.45% NaCl/5% dextrose con-
taining NaHCO3 (180 mmol/m
2/24 h) þ KCl 7.45% (90 ml/
m2/24 h) during the 72 h or 48 h to children treated with
2 g/m2, 5 g/m2 and 1 g/m2, respectively.124
y of hepatotoxicity and myelotoxicity in leukemic children with
rics and Adolescent Medicine (2016), http://dx.doi.org/10.1016/
Q10
Table 2 Demographic features of children.
Dose 1 g/m2
(n Z 17)
2 g/m2
(n Z 14)
5 g/m2
(n Z 17)
Infusions 68 56 68
Gender (F/M) 5/12 7/7 13/4
SR/IR 13/4 13/1 e/17
Age 6.17 (2.94) 3.78 (3.06) 8.23 (5.25)
Immunophenotype Pre B-ALL
(17)
Pre B-ALL
(13)
T-ALL (1)
Pre-B ALL
(16)
T-ALL (1)
SR: Standard risk, IR: Intermediate risk.
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administered via the intravenous route (IV) at a dose of
15 mg/m2 at 42, 48 and 54 h in patients receiving 1 g/m2,
2 g/m2 and 5 g/m2, respectively. A MTX level at
42 h > 1 mmol/L was defined as extended MTX elimination.
These patients were treated with 30 mg/m2 of calcium
leucovorin at 42 h. The MTX serum levels were monitored
until they decreased below 0.25 mmol/L.
The blood toxicity and the liver enzyme levels were
classified based on the Common Terminology Criteria for
Adverse Events 2010 guideline (Table 1) [7]. Myelotoxicity
was defined as hemoglobin (Hb) < 10 g/L and absolute
neutrophil count (ANC) <1  109/L or platelet (PLT) count
<75 109/L. Transaminase levels of5 times the upper limit
were assessed as  grade 3 hepatotoxicity. The reference
range of our hospital for transaminases is 40 IU/L.
The myelotoxicity and hepatotoxicity frequency was
investigated after repeated cycles and then the toxicity
frequencies for the three groups were compared. The
MTX42 levels are the drug concentration values when the
first calcium leucovorin treatment is provided. The MTX42
levels in patients with and without hepatic toxicity were
compared in the patients receiving 2 and 5 g/m2.
The correlation between MTX42h levels and Hb, AST, ALT,
ANC and PLT count were evaluated for each cycle. There
was no evaluation conducted for the patients receiving 1 g/
m2 as their MTX levels were not obtained.
3. Statistical analysis
The analyses were conducted using SPSS 21 software. The
patients were grouped based on drug dose. The normality
of distributions was evaluated with the Kolmogor-
oveSmirnov test. The mean pre- and post-infusion values
were analyzed with the paired sample t-test and the Wil-
coxon test. We used the Analysis of variance (ANOVA) for
independent groups. The comparison of MTX42h levels was
performed using the Mann Whitney U-test. The Pearson
correlation test was used to evaluate the correlation be-
tween variables. All P < .05 values were considered sta-
tistically significant.Table 1 Toxicity criteria according to the Common Ter-
minology Criteria for Adverse Events 2010 guideline.
Grade 1 Grade 2 Grade 3 Grade 4
Hb (g/L) LLN-10 8e10 <8 Life-
threatening
anemia
ANC(109/
L)
LLN-
1.5  1
1.5e1 1e0.5 <0.5
PLT (109/
L)
LLN-75 75e50 50e25 <25
AST and ALT
(IU/L)
>ULN-
3 ULN
3
e5 ULN
5
e20 ULN
>20 ULN
Hb: Hemoglobin, ANC: Absolute neutrophil count, PLT: Platelet
count, AST: Aspartate aminotransferase, ALT: Alanine amino-
transferase, LLN: lower limit of normal, ULN: upper limit of
normal.
Please cite this article in press as: O¨zdemir ZC, et al., The frequenc
different high doses of methotrexate, International Journal of Pediat
j.ijpam.2016.08.0084. Results
In this study, there were 192 HDMTX infusions delivered to
48 leukemic children (1 g/m2: 17 children, 68 infusions; 2 g/
m2: 14 children, 56 infusions; 5 g/m2: 17 children, 68 in-
fusions) between 2 and 17 years of age. There were 25
females (52%) and 23 males (48%). The mean patient age of
those who received 1 g/m2, 2 g/m2 and 5 g/m2 were 6.17
(2.94) years, 3.78 (3.06) years and 8.23 (5.25) years,
respectively. There were 46 cases with pre- B ALL and 2
cases with ALL. The demographic characteristics of the
children are presented in Table 2.
We detected a statistically significant reduction in Hb
level and ANC (P< .05, P < .001, respectively) by comparing
the mean laboratory data obtained prior to drug infusion
and at day 7. There was no statistically significant differ-
ence in the PLT count. However, there was a statistically
significant increase in ALT and AST levels (P < .001, for
both) (Table 3).
Neutropenia  grade 3 developed in 23.5%, 19.6% and
20.5% of the HDMTX infusions in the patients receiving 1, 2
and 5 g/m2, respectively. Myelotoxicity was observed in 12
(70.5%), 10 (71.4%), and 12 (70.5%) children following 24
(35.2%), 23 (41%), and 23 (33.8%) infusions in patients
receiving 1 g/m2, 2 g/m2 and 5 g/m2, respectively.Table 3 The mean values of Hb, AST, ALT with PLT and
ANC before and after 7 days of HDMTX infusion.
Before infusion After 7 days of
HDMTX infusion
P
Hb (g/L) 10.70 (1.07) 10.47 (1.28) <.05a
ANC(109L) 1663.22 (587.61) 1280.26 (583.54) <.001a
PLT (109L) 195875.00
(148812.50
e237062.50)
182750.00
(142750.00
e226500.00)
>.05b
ALT (IU/L) 24.25 (19.75
e35.68)
51.50 (32.62
e123.37)
<.001b
AST (IU/L) 26.50 (24.06
e30.18)
40.37 (29.62
e62.00)
<.001b
Hb: Hemoglobin, ANC: Absolute neutrophil count, PLT: Platelet
count, ALT: Alanine aminotransferase, AST: Aspartate
aminotransferase.
a Paired sample t test.
b Wilcoxon test.
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Table 4 Toxicity frequencies with regard to doses. Q11
1 g/m2 2 g/m2 5 g/m2
_Infusion (n/%) Patient (n/%) _Infusion (n/%) Patient (n/%) _Infusion (n/%) Patient (n/%)
ANC<1  109/L 16 (%23.5) 13 (%76.4) 11 (%19.6) 9 (%64.2) 14 (%20.5) 10 (%58.8)
PLT<75  109/L 3 (%4.4) 3 (%17.6) 6 (%10.7) 2 (%14.2) 1 (%1.4) 1 (%5.8)
Hb < 10 g/L & ANC<1  109/L 21 (%30.8) 9 (%52.9) 17 (%30.3) 8 (%57.2) 22 (%32.4) 11 (%64.7)
Myelotoxicity 24 (%35.2) 12 (%70.5) 23 (%41) 10 (%71.4) 23 (%33.8) 12 (%70.5)
ALT 40e120 IU/L (Grade 1) 21 (%25) 13 (%76.4) 19 (%33.9) 11 (%78.5) 16 (%23.5) 9 (%52.9)
ALT 120e200 (Grade 2) 5 (%7.3) 5 (%29.4) 5 (%8.9) 4 (%28.5) 3 (%4.4) 3 (%17.6)
ALT 200e800 (Grade 3) 8 (%11.7) 4 (%23.5) 5 (%8.9) 4 (%28.5) 5 (%7.3) 4 (%23.5)
ALT>800 (Grade 4) 1 1 1 1 e e
Hepatotoxicity grade‡ 3 9 (%13.2) 5 (%29.4) 6 (%10.7) 5 (%35.7) 5 (%7.3) 4 (%23.5)
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IJPAM91_proof ■ 12 September 2016 ■ 4/7Hepatotoxicity  grade 3 was detected in 5 (29.4%), 5
(35.7%), and 4 (23.5%) patients after 9 (13.2%), 7 (12.5%)
and 8 (11.7%) infusions in children receiving 1 g/m2, 2 g/m2
and 5 g/m2, respectively (Table 4). There was no statisti-
cally difference in the frequency of myelotoxicity and
hepatotoxicity grade 3 (Table 5).
The frequency of grade 3 hepatotoxicity was 2-fold
higher than myelotoxicity after the 1st cycle in cases
receiving 5 g/m2. The frequency of myelotoxicity increased
in repeated cycles in patients receiving 5 g/m2. The fre-
quency of myelotoxicity showed variability among repeated
cycles in the patients receiving 1 g/m2 and 2 g/m2. There
was a reduction in the frequency of hepatotoxicity
observed for all three dose groups after repeated cycles
(Fig. 1).
The data revealed 13 of 22 patients (59%) (5 patients;
2 g/m2, 8 patients; 5 g/m2) who developed myelotoxicity
and 5 of 9 patients (55%) (4 patients; 2 g/m2 and 1 patient;
5 g/m2) who developed hepatic toxicity had extended MTX
elimination.
There was no difference in MTX42 levels between the
patients with and without hematologic toxicity or the pa-
tients with and without hepatotoxicity (P > .05, all) (Tables
6 and 7). There was no correlation observed between MTX42
levels and the values of Hb, AST, ALT, ANC and PLT count
(P < .05, for all).
5. Discussion
The most commonly described side-effects of MTX therapy
are myelosuppression, acute liver toxicity, nephrotoxicity,
mucositis, and neurotoxicity [4,8e12]. Shimasaki et al [3]
reported that the only factor that affected HDMTX-Table 5 Comparison of the frequency of myelotoxicity
and hepatotoxicity grade 3.
1 g/m2 2 g/m2 5 g/m2 Pa
Myelotoxicity 24 (%
35.2)
21 (%
37.5)
23 (%
33.8)
>.05
Hepatotoxicity
grade 3
9 (%13.2) 7 (%12.5) 8 (%11.7) >.05
a One way ANNOVA.
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different high doses of methotrexate, International Journal of Pediat
j.ijpam.2016.08.008associated toxicity development was high MTX levels.
Additionally, genetic differences affecting the absorption,
distribution, metabolism and expression of the drug were
also significantly involved. The chemotherapeutics used in
combination with HDMTX may also affect toxicity. Previous
studies reported that using HDMTX with increased doses of
6MP may also increase hematologic and hepatic toxicity
[13,14].
Prior studies have reported that there are different ra-
tios for the frequency of HDMTX toxicity. Kapoor et al [15]
detected neutropenia  grade 3 (ANC < 1  109/L) in 24.8%
of the infusions in patients receiving HDMTX at 5 g/m2. In
our study, neutropenia  grade 3 developed in 23.5%, 19.6%
and 20.5% of the HDMTX infusions at doses of 1, 2 and 5 g/
m2, respectively (Table 4). The toxicity rates in our study
were similar to each other and were slightly lower than
those reported in other studies. In the same study, tran-
sient elevation of transaminases occurred in 35% of cycles
and most were grade 1 and 2 (32%), as defined by serum ALT
levels up to 5 times above normal (grade 3 and 4 in 3 cycles)
levels. In our study, hepatotoxicity grade 3 was detected
in 13.2%, 12.5% and 11.7% of the HDMTX infusions for pa-
tients 1, 2 and 5 g/m2, respectively (Tables 4 and 5). Our
rates for hepatotoxicity  grade 3 were higher. Tsurasawa
et al [16] reported that the hepatic and gastrointestinal
system toxicity was higher after first drug administration
and was followed by a sharp reduction in toxicity incidence
in the subsequent cycles. In contrast to non-hematologic
toxicity, the incidence of hematologic toxicity varied
slightly along with HDMTX cycles. Ridolfi et al [17] reported
that there was no increase in hematologic and hepatic
toxicity with repeated drug administrations. Rask et al [4]
identified a significant correlation between leukopenia
and cycle count. However, there is no significant correla-
tion between leukopenia and clinical or pharmacokinetic
parameters. Our study demonstrated the frequency of he-
matologic toxicity changed with repeated infusions. We
found that the frequency of hematologic toxicity gradually
increased in the group receiving 5 g/m2 (Fig. 1). It is
thought that the increase in myelosuppression in subse-
quent cycles is related to the accumulation of cytotoxic
metabolites of MTX and 6MP [4].
The frequency of hepatotoxicity was higher with the first
infusion in all three doses and then showed a subsequent
reduction (Fig. 1). The reduction in hepatotoxicity after the
first infusion could be explained by the significantlyy of hepatotoxicity and myelotoxicity in leukemic children with
rics and Adolescent Medicine (2016), http://dx.doi.org/10.1016/
6Figure 1 Myelotoxicity and hepatotoxicity grade 3 in HDMTX cycles.
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IJPAM91_proof ■ 12 September 2016 ■ 5/7increased plasma folate concentration resulting from
repeated leucovorin administrations during HDMTX cycles
[18].
Holmboe et al [19] reported that osteosarcoma patients
receiving HDMTX showed a relationship between the levels
of peak ALT and 7-OH MTX, which is a metabolite of MTX.
According to the results of their study, there is no rela-
tionship between the levels of peak ALT and peak MTX
levels. Additionally, Csordas et al [6] did not identify any
correlation between bone marrow toxicity and the levels of
serum MTX. In the same study, the authors determined that
there was no correlation between 7-OH MTX levels and
hepatotoxicity or bone marrow toxicity. However, accord-
ing to Rask et al [4] an important risk factor for temporary
increases in ALT levels is the extended presence of high
serum MTX levels.
In this study, the MTX42 levels in patients with myelo-
toxicity and hepatotoxicity were not different from pa-
tients without toxicity (Tables 6 and 7). However, MTX
elimination was extended in 59% of the patients with he-
matologic toxicity and 55% of patients with hepatic toxicity.Table 6 Comparison of MTX42h levels in patients with and witho
cycles.
2 g/m2 Pa
Hematologic toxicityþ Hematologic toxicity-
Cycles 1 1.04 (0.29e2.02) (n Z 8) 0.53 (0.22e0.90) (n Z 6) >.
Cycles 2 0.96 (0.39e1.08) (n Z 5) 0.70 (0.28e0.83) (n Z 9) >.
Cycles 3 0.31 (0.22e1.22) (n Z 6) 0.50 (0.48e0.99) (n Z 8) >.
Cycles 4 0.56 (0.16e0.95) (n Z 4) 0.58 (0.33e2.23) (n Z 10) >.
The first row shows MTX levels at 42 h and the second row shows num
a Mann Whitney U- test.
Please cite this article in press as: O¨zdemir ZC, et al., The frequenc
different high doses of methotrexate, International Journal of Pediat
j.ijpam.2016.08.008These results suggest the levels of MTX42 are not able to
identify hematologic and hepatic toxicity risks.
Previous studies have shown using 6MP in combination
with HDMTX affects toxicity frequency. Frandsen et al [20]
found patients receiving increased 6MP (50e75 mg/m2)
doses did not experience more toxicity than patients
receiving 25 mg/m2 per day. Furthermore, Niekerk et al [13]Q
reported that when they compared patients receiving 5 g/
m2 HDMTX with patients receiving different doses of 6MP the
hepatic and hematologic toxicity were higher in the patients
receiving 75 mg/m2 than those receiving 25 mg/m2. The
authors speculated the cause of these results was the
increasing cytotoxic effect because MTX increases both the
bioavailability and enzymatic activation of 6MP [14,21]. The
same researchers also found hepatotoxicity was higher in
patients not receiving 6MP than the patients receiving 6MP
and there was no logical explanation for this result. There is
a strong correlation between the severity of myelosup-
pression, delayed treatment and the dose of 6MP [13,22].
Levinsen et al [14] reported increased levels of 6MP are
related to both hematologic and hepatic toxicity.ut hematologic toxicity and distribution with reference to the
5 g/m2 Pa
Hematologic toxicityþ Hematologic toxicity-
05 0.64 (0.52e1.53) (n Z 3) 0.92 (0.52e1.17) (n Z 14) >.05
05 0.97 (0.34e1.65) (n Z 5) 0.54 (0.41e1.01) (n Z 12) >.05
05 0.95 (0.38e1.62) (n Z 6) 0.45 (0.28e1.06) (n Z 11) >.05
05 0.68 (0.29e1.94) (n Z 7) 0.47 (0.28e0.97) (n Z 10) >.05
ber of patients.
111
112
113
114
115
116
117
118
119
120
121
122
123
124
y of hepatotoxicity and myelotoxicity in leukemic children with
rics and Adolescent Medicine (2016), http://dx.doi.org/10.1016/
Q7
Table 7 Comparison of MTX42h levels in patients with and without hepatotoxicity and distribution with reference to the
cycles.
2 g/m2 Pa 5 g/m2 Pa
Hepatotoxicityþ Hepatotoxicity- Hepatotoxicityþ Hepatotoxicity-
Cycles 1 0.29 (0.22e2.02) (n Z 8) 0.80 (0.38e1.06) (n Z 6) >.05 0.77 (0.444e1.92) (n Z 6) 0.88 (0.56e1.20) (n Z 11) >.05
Cycles 2 0.86 (0.43e1.02) (n Z 5) 0.70 (0.25e0.99) (n Z 9) >.05 0.47 (0.28e0.99) (n Z 2) 0.70 (0.44e1,12) (n Z 15) >.05
Cycles 3 0.88 (0.31e1.2) (n Z 3) 0.49 (0.26e0.86) (n Z 11) >.05 0.37 (0.24e0.90) (n Z 2) 0.68 (0.42e1,09) (n Z 15) >.05
Cycles 4 0.94 (0.72e1.1) (n Z 2) 0.40 (0.17e1.06) (n Z 12) >.05 0.42 (0.26e1.48) (n Z 2) 0.60 (0.28e0.99) (n Z 15) >.05
The first row shows MTX levels at 42 nd h and the second row shows number of patients.
a Mann Whitney U-test.
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IJPAM91_proof ■ 12 September 2016 ■ 6/7The patients received standard 6MP doses (25 mg/m2).
Therefore, the dose of 6MP was not an important factor
affecting the frequency of toxicity. However, it is important
to consider the individual differences in the metabolism of
6MP.
6. Conclusion
Our results indicate that myelotoxicity occurred in
approximately 35% of patients and that severe hepatic
toxicity occurred in 10% of treated patients. There was no
increase in toxicity due to dose administration. Although
the frequency of myelotoxicity increased in patients
receiving 5 g/m2, the hepatotoxicity frequency decreased.
There is no difference between MTX42h levels in patients
with and without toxicity. Furthermore, there is no corre-
lation between blood count, AST-ALT levels and MTX42h
levels. These results suggest that MTX42h levels are not able
to predict hematologic and hepatic toxicity. Thus, there is a
need for further studies to confirm these results because
our patient population is limited.
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